# Phase 1/2 Triple Negative Breast Neoplasms trials: 62 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 62 trials in phase 1/2 for Triple Negative Breast Neoplasms that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Triple Negative Breast Neoplasms trials: 62 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/triple-negative-breast-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 62
- Recruiting or not yet: 62
- Read on: November 19, 2026

## Trials

The 25 newest of 62, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 27, 2026 | NCT07899632 | A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors | Medsyn Biopharma, LLC | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer... | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07899632) |
| August 13, 2026 | NCT07762703 | Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS\<10), gBRCA Negative, Triple... | BreakBio Corp | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07762703) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| August 4, 2026 | NCT07743723 | A Study of IOV-5001 in Adults With Advanced Solid Tumors | Iovance Biotherapeutics, Inc. | Phase 1/2 | Not yet recruiting | Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer, Head and... | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743723) |
| July 31, 2026 | NCT07739485 | Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Triple -Negative Breast Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07739485) |
| July 28, 2026 | NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | CoRegen, Inc. | Phase 1/2 | Not yet recruiting | HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Prostate Cancer | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730125) |
| July 13, 2026 | NCT07698106 | Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC | University Health Network, Toronto | Phase 1/2 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07698106) |
| July 2, 2026 | NCT07681297 | Tislelizumab in Combination With Bevacizumab and Capecitabine in Advanced Solid Tumors With Evaluation in Immunotherapy-Resistant and... | National University Hospital, Singapore | Phase 1/2 | Not yet recruiting | Advanced Solid Tumor Cancer, Triple-Negative Breast Cancer (TNBC), CNS Disease, Breast Cancer | 154 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07681297) |
| May 12, 2026 | NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | Telomir Pharmaceuticals, Inc. | Phase 1/2 | Not yet recruiting | Triple-Negative Breast Cancer (TNBC), Advanced Triple-Negative Breast Cancer, Metastatic Triple-negative Breast Cancer | 76 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581314) |
| April 13, 2026 | NCT07523529 | Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Unresectable, Metastatic | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523529) |
| April 6, 2026 | NCT07510802 | Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC | Beijing Biotech | Phase 1/2 | Recruiting | Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07510802) |
| March 20, 2026 | NCT07486089 | Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) | Beijing Biotech | Phase 1/2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic), HER2-positive Breast Cancer, Triple-Negative Breast Cancer (TNBC) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07486089) |
| January 14, 2026 | NCT07339176 | Intratumoral N17350 in Advanced Solid Tumors | Onchilles Pharma Inc | Phase 1/2 | Recruiting | Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma, Head and Neck... | 275 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07339176) |
| December 15, 2025 | NCT07281976 | A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer | Nanjing Leads Biolabs Co.,Ltd | Phase 1/2 | Recruiting | Triple Negative Breast Cancer | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07281976) |
| October 20, 2025 | NCT07217990 | Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer | Ohio State University Comprehensive Cancer Center | Phase 1/2 | Not yet recruiting | Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07217990) |
| October 6, 2025 | NCT07208149 | A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) | Shenzhen Majory Biotechnology Co., Ltd. | Phase 1/2 | Recruiting | Triple-Negative Breast Cancer (TNBC) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07208149) |
| September 24, 2025 | NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Radiopharm Theranostics, Ltd | Phase 1/2 | Recruiting | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer... | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189871) |
| September 9, 2025 | NCT07161791 | Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer | Harbin Medical University | Phase 1/2 | Not yet recruiting | Breast Cancer, Triple Negative Breast Cancer (TNBC) | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07161791) |
| August 24, 2025 | NCT07139470 | Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer | Tianjin Medical University Cancer Institute and Hospital | Phase 1/2 | Not yet recruiting | Triple Negative Breast Cancer | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07139470) |
| August 11, 2025 | NCT07115043 | A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors | AstraZeneca | Phase 1/2 | Recruiting | Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115043) |
| July 14, 2025 | NCT07064018 | Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | University of California, Irvine | Phase 1/2 | Recruiting | Soft-tissue Sarcoma, Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Ovarian Cancer, KRAS... | 67 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07064018) |
| June 9, 2025 | NCT07011654 | Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) | M.D. Anderson Cancer Center | Phase 1/2 | Recruiting | Metastatic Triple-Negative Breast Cancer | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07011654) |
| May 9, 2025 | NCT06963905 | Saci Nivo Rela for TNBC | Yale University | Phase 1/2 | Recruiting | Metastatic Triple-negative Breast Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06963905) |
| April 15, 2025 | NCT06926920 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | Gilead Sciences | Phase 1/2 | Recruiting | Triple Negative Breast Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926920) |
| March 17, 2025 | NCT06880029 | Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy | Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. | Phase 1/2 | Recruiting | Triple Negative Breast Cancer (TNBC) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06880029) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National University Hospital, Singapore | 3 |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 3 |
| Cancer Research UK | 2 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 2 |
| [Gilead Sciences](https://specstream.ai/data/clinical-trials/company/gilead-sciences) | 2 |
| Onchilles Pharma Inc | 1 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 1 |
| Volastra Therapeutics, Inc. | 1 |
| QuantumLeap Healthcare Collaborative | 1 |
| Dartmouth-Hitchcock Medical Center | 1 |
| Arvinas Inc. | 1 |
| PMV Pharmaceuticals, Inc | 1 |
| BreakBio Corp | 1 |
| Yale University | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
| University Health Network, Toronto | 1 |
| Iovance Biotherapeutics, Inc. | 1 |
| Essen Biotech | 1 |
| Fundacio Clinic Barcelona | 1 |
| Medsyn Biopharma, LLC | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| St Vincent's Hospital, Sydney | 1 |
| Avenzo Therapeutics, Inc. | 1 |
| Nova Scotia Health Authority | 1 |
| Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 32 |
| Australia | 10 |
| China | 10 |
| United Kingdom | 7 |
| Spain | 7 |
| France | 6 |
| Japan | 5 |
| South Korea | 4 |
| Singapore | 4 |
| Canada | 4 |
| Germany | 3 |
| Italy | 3 |
| Netherlands | 2 |
| Belgium | 2 |
| Israel | 2 |
| Chile | 1 |
| Taiwan | 1 |
| Portugal | 1 |
| Romania | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Genetics practices in the United States](https://specstream.ai/data/businesses/genetics-practices/united-states)
- [Duplication companies in the United States](https://specstream.ai/data/businesses/duplication-companies/united-states)
- [Carpet installation companies in the United States](https://specstream.ai/data/businesses/carpet-installation-companies/united-states)
- [B2B energy and utility companies in the United States](https://specstream.ai/data/businesses/b2b-energy-and-utility-companies/united-states)
- [Vietnamese restaurants in the United States](https://specstream.ai/data/businesses/vietnamese-restaurants/united-states)
- [Software development companies in the United States](https://specstream.ai/data/businesses/software-development-companies/united-states)
